The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Predicting MM progression
Mark Bustoros
• 12 Sep 2019
Mark Bustoros, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses how the use of genomic predictors in multiple myeloma (MM) allows for the greater stratification of patients and thus provides clinicians with an increased capacity to predict who is most likely to progress. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
